Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,335.00
Bid: 2,334.00
Ask: 2,336.00
Change: 51.00 (2.23%)
Spread: 2.00 (0.086%)
Open: 2,291.00
High: 2,337.00
Low: 2,284.00
Prev. Close: 2,284.00
HLMA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

22 Sep 2022 07:00

RNS Number : 2266A
Halma PLC
22 September 2022
 

Trading update

Halma, the global group of life-saving technology companies focused on growing a safer, cleaner and healthier future, today releases its scheduled trading update.

Good progress in the first half and unchanged guidance for the full year

Halma has made good progress in the first half of the financial year to date, in line with the Board's expectations, even though the operational environment remains challenging. Our companies have continued to see strong demand for their products and services, with order intake strongly ahead of both revenue in the year to date and order intake for the same period last year. We expect to report good organic constant currency revenue growth in the first half of the year, against a very strong comparative period last year, and Return on Sales1 in line with levels typically seen in first halves of the years prior to the COVID pandemic.

Our guidance for revenue growth and Return on Sales1 for the full financial year to March 2023 is unchanged from that given in our results announcement in June3.

Our strong underlying cash generation and robust financial position is supporting increased strategic investment in future organic growth, as well as providing capacity to fund acquisitions and our progressive dividend policy. In the first half of the year, we expect our cash conversion to reflect further targeted investment in working capital to maintain supply chain resilience and support growth.

Good organic constant currency revenue growth in all sectors

All sectors have delivered good organic constant currency revenue growth in the year to date and have also benefited from recent acquisitions, with the largest inorganic contribution being in the Environmental & Analysis sector, and more modest benefits in the Safety and Healthcare sectors. The Safety sector's performance will also reflect the impact of the disposal of Texecom made in the first half of last year.

By geography, there has been organic constant currency revenue growth in the first half of this year in all major regions. The USA and Mainland Europe have delivered good organic constant currency revenue growth to date, while the UK and Asia Pacific have grown modestly against very strong comparatives. Organic constant currency revenue growth in the remaining smaller regions was strong in aggregate.

The depreciation of Sterling is having a positive currency translation effect on the Group's results; we expect this effect to continue in the second half of the year5.

Further progress in M&A; healthy acquisition pipeline

Following a very active 2021/22 financial year, in which we made 13 acquisitions, we made one acquisition in the first half of this financial year. In April, we acquired Deep Trekker, an Ontario-based manufacturer of remotely operated underwater robots used for inspection, surveying, analysis and maintenance for Can$60m (approximately £36m) on a cash and debt free basis.

We have a promising acquisition pipeline across all three sectors. We continue to actively manage our portfolio of global businesses to ensure that it continues to deliver strong growth and returns over the long term and is aligned with our purpose of growing a safer, cleaner, healthier future for everyone, every day.

Half Year Results

The results for the half year ending 30 September 2022 will be released on Thursday 17 November 2022.

For further information, please contact:

Halma plc

Andrew Williams, Group Chief Executive +44 (0)1494 721111

Marc Ronchetti, Chief Financial Officer, Chief Executive Designate

Charles King, Head of Investor Relations +44 (0) 7776 685948

Clayton Hirst, Director of Corporate Affairs +44 (0) 7384 796 013

MHP Communications

Andrew Jaques / Rachel Farrington +44 (0)20 3128 8613

A copy of this announcement, together with other information about Halma, may be viewed on its website: www.halma.com

Notes:

1. Return on Sales is defined as Adjusted profit before tax2 from continuing operations expressed as a percentage of revenue from continuing operations.

2. Adjusted profit before tax is before amortisation and impairment of acquired intangible assets, acquisition items, restructuring costs and profit or loss on disposal of businesses.

3. The following guidance was given in our Full Year 2022 results announcement in June 2022: "We expect to deliver continued growth and maintain high returns in the 2022/23 financial year, with good single digit percentage organic constant currency revenue growth and a Return on Sales similar to the second half of the 2021/22 financial year."

4. This Trading Update is based upon unaudited management accounts information. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks.

5. Sterling has weakened in the year relative to many currencies, including the US Dollar and Euro. If current exchange rates continue throughout the rest of the current financial year, the currency translation impact on the Group's results is expected to be positive. Based on exchange rates of Sterling/US Dollar 1:1.18 and Sterling/Euro 1:1.16, we would expect approximately a £135m positive revenue effect and approximately a £30m positive profit effect in 2022/23, compared to 2021/22.

6. A copy of this announcement, together with other information about Halma, may be viewed on its website at www.halma.com.

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day.

Its purpose defines the three broad market areas where it operates:

· Safety: protecting life as populations grow and protecting worker safety.

· Environment: improving food and water quality, and monitoring air pollution.

· Healthcare: meeting rising healthcare demand as growing populations age and lifestyles change.

It employs over 7,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

For the past three years Halma has been named one of Britain's Most Admired Companies by Management Today.

For more information www.halma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDGGDCSBDDGDB
Date   Source Headline
9th Feb 20183:49 pmRNSDirector/PDMR Shareholding
7th Feb 20182:00 pmRNSInvestor Event
16th Jan 20187:00 amRNSUS Tax Reform Update
21st Dec 20179:00 amRNSAcquisition
5th Dec 201710:10 amRNSDirector/PDMR Shareholding
21st Nov 20173:10 pmRNSDoc re. Half Yearly Report
21st Nov 20177:00 amRNSHalf-year Report
1st Nov 20177:00 amRNSAcquisition
4th Oct 20175:54 pmRNSDirector/PDMR Shareholding
28th Sep 20179:57 amRNSDirector/PDMR Shareholding
27th Sep 20177:00 amRNSTrading Statement
11th Sep 201712:19 pmRNSDirector Declaration
7th Sep 20179:27 amRNSDirector Declaration
1st Sep 20175:08 pmRNSTotal Voting Rights
16th Aug 20174:02 pmRNSDirector/PDMR Shareholding
7th Aug 20177:00 amRNSAcquisition
1st Aug 201710:39 amRNSTotal Voting Rights
31st Jul 201712:00 pmRNSNotice of Board Change
20th Jul 20173:57 pmRNSResult of AGM
19th Jul 20172:21 pmRNSDirector Declaration
4th Jul 20173:39 pmRNSDirector/PDMR Shareholding
3rd Jul 201711:29 amRNSTotal Voting Rights
21st Jun 20175:22 pmRNSAnnual Financial Report
13th Jun 20177:00 amRNSFinal Results
1st Jun 20173:02 pmRNSTotal Voting Rights
30th May 201711:00 amRNSNotice of Results
2nd May 20173:39 pmRNSTotal Voting Rights
6th Apr 20179:00 amRNSNotice of Board change
3rd Apr 201711:12 amRNSTotal Voting Rights
23rd Mar 20177:00 amRNSTrading Update and Audit Tender
1st Mar 201712:41 pmRNSTotal Voting Rights
13th Feb 20174:06 pmRNSHolding(s) in Company
1st Feb 201712:07 pmRNSTotal Voting Rights
9th Jan 20179:00 amRNSAcquisition of FluxData
3rd Jan 20174:02 pmRNSTotal Voting Rights
1st Dec 201611:37 amRNSTotal Voting Rights
28th Nov 20163:05 pmRNSDirector/PDMR Shareholding
24th Nov 20164:18 pmRNSDirector/PDMR Shareholding
22nd Nov 20164:35 pmRNSDoc re. Half Yearly Report
22nd Nov 20167:00 amRNSHalf-year Report
1st Nov 20164:43 pmRNSTotal Voting Rights
5th Oct 20165:51 pmRNSDirector/PDMR Shareholding
3rd Oct 20164:31 pmRNSTotal Voting Rights
29th Sep 201610:00 amRNSInvestor Event
27th Sep 20169:37 amRNSDirectorate Change
23rd Sep 20164:27 pmRNSDirectorate Change
1st Sep 20165:25 pmRNSTotal Voting Rights
22nd Aug 20163:54 pmRNSDirector/PDMR Shareholding
10th Aug 20163:26 pmRNSDirector/PDMR Shareholding
1st Aug 20169:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.